Page 157 - 《南京医科大学学报（自然科学版）》2025年第9期

第45卷第9期 辛 亮，张 岭，杨克俭. 人偏肺病毒疫苗研究进展［J］.
2025年9月 南京医科大学学报（自然科学版），2025，45（9）：1362-1369 ·1369 ·

1365）［EB/OL］.（2023⁃05⁃04）［2024⁃12⁃04］. https：// Vaccines，2019，7（4）：164
s29. q4cdn. com/435878511/files/doc_downloads/program ［31］STEWART⁃JONES G B E，GORMAN J，OU L，et al. Inter⁃
_detail/2023/05/RSV⁃hMPV⁃05⁃04⁃23.pdf protomer disulfide⁃stabilized variants of the human meta⁃
［22］SANOFI. Study of the safety and immune response of an pneumovirus fusion glycoprotein induce high titer⁃neutral⁃
investigational mRNA vaccine for the prevention of respi⁃ izing responses［J］. Proc Natl Acad Sci U S A，2021，118
ratory syncytial virus and/or human metapneumovirus in （39）：e2106196118
participants aged 18 to 49 years and 60 years and older ［32］OU L，CHEN S J，TENG I T，et al. Structure⁃based design
［EB/OL］.（2024 ⁃ 08 ⁃ 13）［2024 ⁃ 09 ⁃ 11］. https：//www. of a single⁃chain triple⁃disulfide⁃stabilized fusion⁃glyco⁃
sanofistudies.com/us/en/listing/312907/study⁃of⁃the⁃safety protein trimer that elicits high⁃titer neutralizing responses
［23］SANOFI. Study of a respiratory syncytial virus/human against human metapneumovirus［J］. PLoS Pathog，2023，
metapneumovirus vaccine candidate［EB/OL］.（2024⁃08⁃ 19（9）：e1011584
14）［2024⁃09⁃11］. https：//www. sanofistudies. com/us/en/ ［33］KWONG P，JOYCE M G，ZHANG B，et al. Recombinant
listing/312867/study⁃of⁃a⁃respiratory⁃2/ metapneumovirus F proteins and their use：US11027007
［24］SANOFI. Study to evaluate the safety and immune re⁃ ［P］. 2021⁃06⁃08
sponse of an investigational vaccine for the prevention of ［34］BAKKERS M J G，RITSCHEL T，TIEMESSEN M，et al.
RSV（respiratory syncytial virus）and hMPV human meta⁃ Efficacious human metapneumovirus vaccine based on AI⁃
pneumovirus infection in participants aged 60 to 75 years guided engineering of a closed prefusion trimer［J］. Nat
［EB/OL］.（2024⁃10⁃09）［2024⁃09⁃03］. https：//clinicaltri⁃ Commun，2024，15（1）：6270
als.gov/study/NCT06583031 ［35］MA F L，CHEN A J，YAO L H，et al. Immunogenicity and
［25］WATTERSON D，WIJESUNDARA D K，MODHIRAN N， protective efficacy of human metapneumovirus virus⁃like
et al. Preclinical development of a molecular clamp⁃stabi⁃ particles produced by a recombinant baculovirus in
lised subunit vaccine for severe acute respiratory syn⁃ mice［J］. Virus Res，2023，336：199215
drome coronavirus 2［J］. Clin Transl Immunology，2021， ［36］PILAEV M，SHEN Y，CARBONNEAU J，et al. Evaluation
10（4）：e1269 of pre⁃ and post⁃fusion human metapneumovirus F pro⁃
［26］AUGUST A，SHAW C A，LEE H，et al. Safety and immu⁃ teins as subunit vaccine candidates in mice［J］. Vaccine，
nogenicity of an mRNA ⁃ based human metapneumovirus 2020，38（9）：2122-2127
and parainfluenza virus type 3 combined vaccine in ［37］HUANG J C，CHOPRA P，LIU L，et al. Structure，immu⁃
healthy adults［J］. Open Forum Infect Dis，2022，9（7）： nogenicity，and conformation⁃dependent receptor binding
ofac206 of the postfusion human metapneumovirus F protein［J］. J
［27］SCHNYDER GHAMLOUSH S，ESSINK B，HU B，et al. Virol，2021，95（18）：e0059321
Safety and immunogenicity of an mRNA ⁃ based hMPV/ ［38］CHAN Y，SASMAL S，STUEBLER A，et al. Human meta⁃
PIV3 combination vaccine in seropositive children［J］. Pe⁃ pneumovirus viral vector⁃based vaccines：WO2023102388
diatrics，2024，153（6）：e2023064748 ［P］. 2022⁃11⁃29
［28］KARRON R A，SAN MATEO J，WANIONEK K，et al. ［39］TIAN C Y，LEI G L，SUN F，et al. A chimeric influenza vi⁃
Evaluation of a live attenuated human metapneumovirus rus vaccine expressing fusion protein epitopes induces
vaccine in adults and children［J］. J Pediatric Infect Dis protection from human metapneumovirus challenge in
Soc，2018，7（1）：86-89 mice［J］. Front Microbiol，2022，13：1012873
［29］VELAYUTHAM T S，IVANCIUC T，GAROFALO R P，et ［40］MCLELLAN J，HSIEH C L. Prefusion⁃stabilized chimeric
al. Role of human metapneumovirus glycoprotein G in hMPV⁃RSV F proteins，WO2023288296［P］. 2022⁃01⁃19
modulation of immune responses［J］. Front Immunol， ［41］MA S Y，ZHU F，XU Y Z，et al. Development of a novel
2022，13：962925 multi⁃epitope mRNA vaccine candidate to combat HMPV
［30］DUBOIS J，PIZZORNO A，CAVANAGH M H，et al. Strain virus［J］. Hum Vaccin Immunother，2023，19（3）：2293300
⁃dependent impact of G and SH deletions provide new in⁃ ［收稿日期］ 2024-10-16
sights for live⁃attenuated HMPV vaccine development［J］. （本文编辑：陈汐敏）